LONDON, February 4 /PRNewswire/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007.

In an interview on CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of RD.

He said:

Now obviously I don't like to see anybody leave the organisation or there to be any job losses. But the reality is that we do, from time to time, need to look at ways in which we can improve our probability of success.

The interview and transcript are available now on, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email or phone +44-207-936-1352.

SOURCE: GlaxoSmithKline

CONTACT: If you would like to contact us, please or phone+44-207-936-1352.